Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 6/20 | 0.50 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | F3 | P13726 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.41 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.41 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14125644 | 0.78 | PARP1 (0.49) | DAOPARP1ALDH1A1F7F3 | |
| SCHEMBL154688 | 0.75 | GPR84 (0.63) | DAOALDH1A1F7F3GPR84 | |
| SCHEMBL17439076 | 0.75 | F7 (0.59) | F7F3GPR84 | |
| SCHEMBL22094461 | 0.74 | PARP1 (0.46) | DAOPARP1ALDH1A1F7F3 | |
| SCHEMBL31308846 | 0.74 | PARP1 (0.46) | DAOPARP1ALDH1A1F7F3 | |
| SCHEMBL28803072 | 0.74 | ALDH1A1 (0.50) | DAOPARP1ALDH1A1F7F3 | |
| SCHEMBL1264071 | 0.74 | PARP1 (0.59) | DAOPARP1ALDH1A1ERCC1ERCC4 | |
| SCHEMBL31160182 | 0.74 | PARP1 (0.59) | DAOPARP1ALDH1A1ERCC1ERCC4 | |
| SCHEMBL25003400 | 0.74 | PARP1 (0.45) | DAOPARP1ALDH1A1F7F3 | |
| SCHEMBL31507102 | 0.74 | PARP1 (0.49) | DAOPARP1ALDH1A1F7F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3037416-A1 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | Bristol-Myers Squibb Holdings Ireland (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-2326624-B1 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2015-10-07 | — | — | EP | disclosed |
| US-8877929-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-04 | — | — | US | disclosed |
| US-8877929-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-11-04 | — | — | US | disclosed |
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-16 | — | — | US | disclosed |
| US-8357806-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-8357806-B2 | Process for synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-22 | — | — | US | disclosed |
| US-20120220774-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-30 | — | — | US | disclosed |
| US-20120220774-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-30 | — | — | US | disclosed |
| US-8207341-B2 | Process or synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| US-8207341-B2 | Process or synthesizing substituted isoquinolines | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-06-26 | — | — | US | disclosed |
| WO-2010027889-A2 | PROCESS FOR SYNTHESIZING SUBSTITUTED ISOQUINOLINES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-04 | — | — | US | disclosed |
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | BRISTOL-MYERS SQUIBB COMPANY | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056792-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | DAO 1636/4885PARP1 295/4885ALDH1A1 1643/4885 |
| US-20130123503-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | DAO 1636/4885PARP1 295/4885ALDH1A1 1643/4885 |
| US-20120220774-A1 | Process for Synthesizing Substituted Isoquinolines | POLQ, SFPQ, SYNCRIP | DAO 1636/4885PARP1 295/4885ALDH1A1 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.